Xeris Biopharma Holdings, Inc. (XERS) AI Stock Analysis

Xeris Biopharma Holdings, Inc. develops and commercializes therapies across endocrinology, neurology, and gastroenterology. Its commercial portfolio features Gvoke, a ready-to-use liquid glucagon for the rapid treatment of severe hypoglycemia; Keveyis, indicated for primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for endogenous hypercortisolemia in adult patients with Cushing's syndrome. The company utilizes proprietary formulation technology platforms, XeriSol and XeriJect, to advance development programs that expand its products into new indications. Founded in 2005 and based in Chicago, Illinois, Xeris employs 435 people and pursues treatments for complex medical conditions through proprietary science and strategic partnerships.

Annual revenue grew from $49.6M in FY2021 to $291.8M in FY2025, representing a 5-year revenue CAGR of 154.7% from FY2020 to FY2025. Gross margin expanded from 73.1% in FY2021 to 81.7% in FY2025. Operating margin turned positive in FY2025 at 8.5%, compared to -232.2% in FY2021, and net income reached $554,000 following a loss of -$54.8M in FY2024. Over the trailing twelve months ending June 30, 2026, revenue stood at $335.4M, with quarterly revenue growing 28.7% year-over-year. Operating margin for the trailing twelve months was 5.6%, while net margin was -5.1% with an EPS of -$0.10.

As of June 30, 2026, Xeris held $121.7M in cash and short-term investments against total debt of $289.4M, leaving net debt of $167.7M. Total assets were $411.9M and the current ratio was 1.45. Shareholders' equity was negative at -$9.7M. In FY2025, operating cash flow turned positive to $28.6M. Capital expenditures totaled $696,000, yielding free cash flow of $27.9M. Xeris directed $10.9M to share buybacks in FY2025, while its share count grew 41.7% over the past 5 years.

Xeris carries a market capitalization of $1.88B and an enterprise value of $1.75B. The stock trades at a forward P/E of 36.9x, an EV-to-EBITDA of 73.1x, and a price-to-sales ratio of 5.6x. These metrics sit above the median of its US-listed Healthcare peers, which reflect a forward P/E of 17.3x, an EV-to-EBITDA of 12.0x, and a price-to-sales ratio of 4.1x. Over the past year, the stock returned 12.8% compared to 16.8% for the S&P 500 (SPY). Over a 5-year period, the stock gained 415.5% versus 83.0% for the index.

Wall Street analyst coverage includes 5 Strong Buy, 1 Buy, and 1 Hold recommendations, with zero Sell ratings. The mean price target is $12.86, representing a 24.7% premium over the last close of $10.31. For the current fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.02 on revenue of $387.9M. For the next fiscal year, 3 analysts project revenue of $480.0M and EPS of $0.37. Xeris beat EPS estimates in 2 of the last 4 quarters. The next earnings date is November 5, 2026.

This page is an AI-written research summary of Xeris Biopharma Holdings, Inc. (XERS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: XERS income statement, XERS balance sheet, XERS key metrics, XERS analyst forecast, XERS chart. See the XERS stock overview for the latest quote and news.